Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 17/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16981012 | 0.83 | RXFP1 (0.47) | MLYCDRXFP1HDAC6 | |
| SCHEMBL11160024 | 0.79 | MLYCD (0.67) | MLYCDTRPV1HDAC6 | |
| SCHEMBL194039 | 0.78 | RXFP1 (0.53) | RXFP1 | |
| SCHEMBL4610860 | 0.77 | MLYCD (0.67) | MLYCDTRPV1CES1 | |
| SCHEMBL1663456 | 0.76 | HCAR3 (0.55) | RXFP1 | |
| SCHEMBL10055051 | 0.76 | RXFP1 (0.56) | RXFP1 | |
| SCHEMBL13384248 | 0.75 | MLYCD (0.59) | MLYCDCES1 | |
| SCHEMBL10024338 | 0.75 | RXFP1 (0.50) | MLYCDRXFP1 | |
| SCHEMBL1879501 | 0.75 | MLYCD (0.56) | MLYCDTRPV1CES1HDAC6 | |
| SCHEMBL13841105 | 0.75 | HSD17B10 (0.51) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476423-B1 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | AMGEN INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7071358-B2 | Arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1476423-A4 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1476423-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | Tularik Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003063576-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | MLYCD 488/4885TRPV1 4109/4885CES1 55/4885 |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | MLYCD 488/4885TRPV1 4109/4885CES1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.